Currently there are no effective targeted therapies for triple negative breast cancer (TNBC).
Introduction:
The CDK4/6 -RB1 axis controls transition through the restriction point in the G1 phase of the cell cycle, and cancers frequently subvert the regulation of this axis to promote proliferation [1, 2] . CDK4/6 inhibition is a proven therapeutic strategy for oestrogen receptor positive (ER+ve) breast cancers [3, 4] , with selective CDK4/6 inhibitors (palbociclib and ribociclib) demonstrating substantial improvements in progression free survival (PALOMA1 [3] , PALOMA2 [5] , PALOMA3 [4] and MONALEESA-2 [6] ) in phase two and three clinical trials.
Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with poor prognosis. Although TNBC may be sensitive to chemotherapy there is a substantial need to identify novel targeted therapeutic strategies. TNBC are a heterogeneous group of tumours with gene expression profiling identifying distinct subgroups [7, 8] , including luminal androgen receptor (LAR), mesenchymal stem like (MSL), mesenchymal (MES), and basal-like [7] . The majority of TNBC fall within the dominant basallike and MES subgroups. TNBC are highly proliferative tumours enriched for high expression of cell cycle genes [7] , yet as a heterogeneous group are considered to be largely resistant to CDK4/6 inhibition [9] , as are many other tumour types.
The determinants of sensitivity to CDK4/6 inhibition are poorly understood. Loss of retinoblastoma protein (RB1) causes resistance to CDK4/6 inhibition [10] , however for the majority of cancers, the factors that determine sensitivity or resistance to CDK4/6 inhibitors are unclear. Recent studies of cell cycle dynamics have redefined our understanding of the mitosis-S phase transition in asynchronously dividing cells [11] [12] [13] , with cells at mitotic exit entering either a quiescent or an active-proliferative state [12, 13] . Here we show that cell cycle exit into a quiescent or proliferative state is a major factor determining sensitivity to CDK4/6 inhibitors. We identify subgroups of TNBC that are highly sensitive to CDK4/6 inhibition, and using a CDK2 activity live-cell reporter [12] we show that CDK2 activity after mitotic exit dictates sensitivity to CDK4/6 inhibition.
Methods

Cell lines
Cell lines were obtained from ATCC or Asterand and maintained according to the manufacturer's instructions. Cell lines were banked in multiple aliquots on receipt, identity confirmed by STR profiling with the PowerPlex 1.2 System (Promega) and tested for mycoplasma every two weeks.
Palbociclib-resistant MFM223pR cells were generated by chronic exposure to increasing concentrations of palbociclib (100, 250, 500, 1000nmol) over 4 months. Drug treatments were replaced every 3-4 days with fresh media.
Antibodies, reagents and constructs
Phospho-RB1 S807/811 (8516), RB1 (9313), Cyclin E1 (HE12; 4129), Cyclin E2 (4132), CDK2 (2546), phospho-CDK2 T160 (2561); CDK4 (12790), Androgen Receptor (3202) were all Cell Signalling Technology, Danvers, MA; p16 F-12 (SC-1661, Santa Cruz), -actin (A5441, Sigma); Cyclin E1 (ab33911) and c-myc (ab32072) were Abcam. Western blot analysis was performed using pre-cast 4-12% SDS gels, as described previously [14] .
Densitometry analysis was performed on western blot films using ImageJ software (National Institute of Health, USA), and expressed relative to their corresponding loading control.
Palbociclib (PD-0332991; SelleckChem) was used at 500nmol, pictilisib (GDC-0941; SelleckChem) at 200nmol, and taselisib (GDC-0032; Genentech) at 100nmol, unless otherwise stated. Palbociclib 500nmol was used for the majority of experiments as previously [10] . No increase in effect on clonogenic growth was observed with doses above 500nmol (Fig. 1A ).
siRNAs were from Thermofisher Scientific: siCCNE1 (#4390824, #4390824, #1299001), siCON1 (#4390843), siCON2 (#4390846) and siUBB (# 4390824).
The CDK2 activity live-cell sensor (CDK2L-GFP) was generated by cloning the C-terminal PSLD region of Human DNA Helicase B (DHB; 957-1087 amino acids) into pIRES-GFP puromicin as described previously [11] . PCNA was tagged at the N terminus with the modified LSS2-mKate fluoro-phore to generate LSS2-mKate-PCNA [15] .
Cell Transfections
For CDK2 activity sensor experiments, cells were transfected with CDK2L-GFP using
Lipofectamine
® 2000 according to the manufacturer's instructions, 48-72 hours prior imaging. For siRNA knockdown experiments, SUM149 cells were transfected with CDK2L-GFP on day one, then GFP-positive cells (3000 cells/well) were FACS-sorted into 384-well plate on day 3, and next siRNA transfection using siCON1 and siCCNE1 was performed with Lipofectamine ® RNAiMAX on day 6, followed by time-lapse imaging on days 9-11. As previously demonstrated, the CDK2L-GFP sensor is not phosphorylated by CDK4/6 [11] , nor by CDK1 [12] .
Time-lapse microscopy
CDK2L-GFP positive cells were FACS sorted into 384 well plates, with 1000 to 3000 cells seeded per well, 24 hours prior time-lapse imaging. Unless specified, drugs or vehicle were added immediately prior time-lapse experiments. Images were taken on a High-content Opera Spinning Disk confocal microscope (PerkinElmer) with 40X water objective, every 10 minutes, in a NA 0.9 humidified environmental chamber at 37 0 C and 5% CO 2 .
To assess the impact of palbociclib on S phase entry in SUM149 cells (Fig. 3A) , palbociclib or vehicle (DMSO) was added 8 hours after initiation of CDK2L-GFP time-lapse imaging, with continued imaging for a further 48 hours. Analysis was restricted to cells that underwent mitosis 1-3 hours prior to adding palbociclib or vehicle (DMSO).
To study stability of CDK2 activity in individual cell clones ( Fig. 5D and Supplementary Fig.   4A ), a single cell was FACS-sorted into each well of the 96 well plate, with single cell sorting confirmed by bright field microscopy. Plates were incubated for 4 weeks to generate clonal populations. Individual wells were transfected with CDK2L-GFP, and 48 hours later imaged using time-lapse microscopy. All examined clonal populations were STR typed.
Image analysis
Time frames of cells transfected with CDK2L-GFP or LSS2-mKate-PCNA were captured at 10 minutes intervals over a 48-72 hours period. Dynamic changes of CDK2L-GFP or LSS2-mKate-PCNA were manually tracked in individual cells using Volocity (PerkinElmer). To quantify CDK2 activity, both nuclear and peri-nuclear cytoplasmic CDK2L-GFP intensity were measured simultaneously. CDK2 activity for each time point was calculated as a ratio of mean GFP fluorescent intensity in the cytoplasm divided by the mean GFP fluorescent intensity in the nucleus. For representation, asynchronous single cell CDK2 activity traces were aligned in silico to time of cytokinesis as T0 (time-point = 0). The CDK2 activity traces were smoothed with a window of 4 data points minimize background noise.
Cell cycle length (hours) was calculated as the time from first cytokinesis to the second cytokinesis. Unless stated otherwise, post-mitotic CDK2 activity was assessed as the CDK2 activity at 2 hours post-cytokinesis, as the first time-point across imaged cell lines that allowed reliable quantification of CDK2 activity after reformation of the nuclear membrane and cell flattening [11] . Cells with CDK2 activity <0.6 at 2 hours post cytokinesis were defined as CDK2 low , and cells with CDK2 activity >0.6 at 2 hours points post cytokinesis were defined as CDK2 high , as previously described [12] . In PCNA tracking experiments Sphase entry was defined a sharp increase in PCNA intensity with the appearance of nucleoli, as previously described [11] . Accumulation of CDK2 activity to a ratio of 1 was used as surrogate for cell cycle entry, as previously demonstrated [12] .
Immunofluorescence
Immediately after time lapse, cells were fixed in 4% paraformaldehyde, washed three times in PBS, permeabilized with 0.2% Triton X-100, and stained at room temperature using mouse and rabbit primary antibodies, detected with corresponding fluorescent secondary antibodies: anti-mouse Alexa Fluor-555 and anti-rabbit Alexa Fluor-647. Nuclear pixels were measured as an output of intensity for each cell, using Columbus™ image data storage and analysis system. 
Assessment of viability and proliferation
All clonogenic assays were conducted in triplicates of 6-well plates, with 1000 to 5000 cells seeded per well 24 hour prior to exposure to the indicated drug concentrations, or vehicle.
Wells were treated continuously for at least 2 weeks replacing media/drug every 3-4 days.
Plates were fixed with tricyclic acid (10%), stained with sulforhodamine B (SRB) and absorbance measured. Absorbance for drug treated wells was expressed relative to the control wells, with subtraction of the background SRB absorbance from an empty well. The mean of at least three replicate wells was calculated for each dose/combination.
Synergy was assessed using SRB absorbance from long-term clonogenic assays. Wells 
Analysis of publically -available data sets
The METABRIC dataset (n=1991) was obtained by application to the European Genomephenome archive [16] . 320 putative TNBC samples were normalised using the beadarray package [17] and classified using TNBC type [18] . 5 samples were then removed as putative ER positive samples leaving 315 for analysis. Segmented (CBS) copy number logR ratios were downloaded and used for copy number analysis, with gain/loss thresholds as previously defined [16] . Heat maps representing key cell cycle genes were generated in R.
For 102 TCGA samples representing TNBC, level 3 RNA-seq data (raw gene counts) was downloaded from the TCGA web site for these samples. The gene counts were normalised using edgeR packages. Copy number, mutation and RPPA data was extracted from cBioPortal using the CGDS-R (http://www.cbioportal.org/cgds_r.jsp). Additional data was downloaded from the Cancer Proteome Atlas project [17] .
Statistical analysisFor in vitro studies, all statistical tests were performed with GraphPad Prism version 6.0. P-values were two-tailed and considered significant if P < 0.05. Error bars represent Standard deviation or SEM of three experiments. Assessment of compound synergy was conducted using Bliss independence score.
Results
Luminal Androgen Receptor (LAR) subtype of triple negative breast cancer is sensitive to CDK4/6 inhibition
We investigated whether the different molecular subgroups of TNBC were sensitive to CDK4/6 inhibition. Clonogenic assays were performed on a panel of 12 RB1 wild-type TNBC cell lines and one RB1 mutant cell line (BT549), with the CDK4/6 inhibitor palbociclib ( out of 10 mice in the palbociclib treatment arm (Fig 1E) .
Palbociclib sensitive cell lines have low post-mitotic CDK2 activity
We hypothesized that sensitivity to CDK4/6 inhibition would be determined by the level of CDK2 activity post-mitosis [12, 13] . To investigate this, we used a live cell fluorescent sensor to measure CDK2 activity (CDK2L) in five RB1 wild type TNBC models ( Fig. 2A) . The CDK2L sensor specifically reports CDK2 activity, and is not phosphorylated by CDK4/6 and nor CDK1 (Methods).
We measured CDK2 activity in individual cells as they transitioned through mitosis and into the next cell cycle. Individual cells in the LAR palbociclib-sensitive cell lines MFM223 and MDAMB435, exited mitosis with low levels of CDK2 activity, which continued to fall during the first two hours post-mitosis ( Fig. 2B and Supplementary Fig. 1A ). The dynamics of CDK2 activity after mitosis in the LAR cells were similar to CDK2 activity levels seen in the ER +ve MCF7 cell line ( Supplementary Fig. 1B ). In contrast, the palbociclib-resistant basal-like cell lines SUM149 and HCC1143 ( Fig. 2C and Supplementary Fig. 1C) , and the MES cell line CAL51 ( Supplementary Fig. 1D ), were predominately composed of cells that exited mitosis and started the next cell cycle with high levels of CDK2 activity, that rapidly accumulated higher levels of CDK2 activity.
To compare CDK2 activity between cell lines, CDK2 activity levels were quantified 2 hours post-cytokinesis, the earliest time-point that allowed accurate quantification after nuclear envelope reformation. Basal-like TNBC cell lines had significantly higher CDK2 activity compared to the LAR cell lines (p<0.0001; Fig. 2D ). Cells which exited mitosis with CDK2 activity <0.6 at 2 hours post cytokinesis were defined as CDK2 low , and cells with CDK2 activity >0.6 at 2 hours post cytokinesis were defined as CDK2 high [12] . Whereas LAR cells exited mitosis with a relatively homogeneous CDK2 low phenotype, basal-like cells existed mitosis with heterogeneous CDK2 activity, with a large proportion of CDK2 high cells (Fig. 2D ).
In (Fig. 3A) , whereas cells that exited mitosis in a CDK2 high state successfully entered the cell cycle despite palbociclib treatment and subsequently underwent a second mitosis (Fig. 3A and Fig. 3B ). Therefore, although the Fig. 2A and 2B ). Collectively this data demonstrates that post-mitotic CDK2 activity dictates sensitivity to CDK4/6 inhibition. CDK2 high cells have sufficient CDK2 activity to bypass the restriction point, the point where CDK4/6 activity is necessary for cell cycle re-entry, resulting in CDK4/6 inhibitor resistance.
We next established whether CDK2 activity at mitotic exit changed after acquired resistance to CDK4/6 inhibitors in LAR cell lines. We generated palbociclib-resistant cells from the MFM223 cell line (MFM223pR) via four months of chronic palbociclib exposure. In clonogenic assays, the MFM223pR were resistant to palbociclib, with a greater proportion of cells in S-phase during palbociclib treatment compared to the parental palbociclib sensitive cell line MFM223 (Fig. 3C ). The MFM223pR model acquired higher protein levels of cyclin E1 and of the activating CDK2 T160 phosphorylation (Fig. 3D) . In MFM223pR cells a new CDK2 high proliferative subpopulation emerged (Fig. 3E) , suggesting that the mechanism of acquired resistance to palbociclib was due to a higher proportion of cells adopting the CDK2 high phenotype.
Temporal dysregulation of Cyclin E1 expression in TNBC cells drives higher CDK2 activity post mitosis
To explore the molecular determinants of CDK2 high cells, we profiled our panel of TNBC cell
lines. The LAR cell lines had both high expression of the androgen receptor (AR) (p=0.01) and absent/low expression of cyclin E1 (p=0.02) (Fig. 4A) . We profiled TNBC tumours using publically available datasets. In both the METABRIC [16] and TCGA [19] datasets TNBC LAR tumours had significantly lower transcriptomic expression levels of CCNE1 (p<0.0001)
and CDK2 (p<0.0001), with higher CDKN1A (p21) levels, as compared to basal-like TNBC (p=0.06) (Fig. 4B, Supplementary Figures 3A and 3B ). Basal-like TNBC tumours had more frequently increased CCNE1 gene copy number than LAR tumours (p=0.008 Fisher's exact test, Fig. 4B ). There was a high correlation between cyclin E1 mRNA with protein levels (r=0.89; Supplementary Fig. 3C and 3D ).
Cyclin E1 is tightly regulated nuclear protein, periodically expressed during the cell cycle, with highest levels occurring during late G1 and early S-phase in non-cancer models [20] .
We investigated the temporal regulation of cyclin E1 in palbociclib sensitive and resistant cell lines, in order to assess whether deregulation of cyclin E1 expression in early G1 promoted the CDK2 high population. To test this we assessed the expression of nuclear cyclin E1 protein in individual cells 1-2 hours post-mitosis by dual immunofluorescence with CDK2L sensor (Methods). Basal-like SUM149 cells had aberrant high cyclin E1 expression post-mitosis (Fig. 4C-4D and Supplementary Fig. 3E ) compared to LAR MDAMB453 cells that had uniform low cyclin E1 expression. This was substantially earlier than the time point where SUM149 cells typically entered S-phase, confirmed using a PCNA sensor ( Supplementary Fig. 3F ). CDK2 high SUM149 cells had higher cyclin E1 protein expression than CDK2 low SUM149 cells (Fig. 4E) . Silencing of cyclin E1 in SUM149 cells resulted in the loss of the CDK2 high population post-mitosis, inducing a CDK2 low phenotype ( Fig. 4F and Supplementary   Fig. 3G ). Furthermore, silencing of cyclin E1 sensitised CAL51 (Fig. 4G and Supplementary   Fig. 3H ), SUM149 ( Supplementary Fig. 3I ) and MFM223pR to palbociclib, with minimal effects upon parental MFM223 cells that had low cyclin E1 expression (Fig. 4H) . Cyclin E1 silencing, without CDK4/6 inhibition, did not substantially reduce BrdU incorporation, likely due to redundancy between different CDKs and cyclins. Our data suggested that aberrant cyclin E1 expression immediately post-mitosis, promoted the CDK2 high phenotype and resistance to CDK4/6 inhibition.
The CDK2 high phenotype is determined pre-mitosis
We next addressed whether post-mitotic activity was determined pre-mitosis, as has been shown in non-cancer models [12] . SUM149 and CAL51 sister cell pairs, generated from the same mitosis, shared similar post-mitotic CDK2 activity ( Fig. 5A and Fig. 5B ) suggesting that the level of CDK2 activity post-mitosis was determined prior to cytokinesis. SUM149 cells with higher pre-mitotic CDK2 activity (2 hours prior to mitosis), generated daughter cells that entered S-phase despite CDK4/6 inhibition ( Fig. 5C ), whereas cells with lower pre-mitotic CDK2 activity were arrested by CDK4/6 inhibition (p=0.016).
Having demonstrated that post-mitotic CDK2 activity was determined pre-cytokinesis, we investigated whether this was due to the existence of fixed sub-population of CDK2 high cells, or whether CDK2 high and CDK2 low populations inter-converted. To test the long-term stability of the CDK2 low and CDK2 high subpopulations, we FACS sorted a single SUM149 cell ( Fig.   5D ) and CAL51 cell ( Supplementary Fig. 4A ) into 96 well plates, confirmed single-cell seeding by microscopy, and assessed CDK2 activity in the resulting single cell clones after four weeks of multiplication. In general, clonal populations recapitulated variability in CDK2 high and CDK2 low populations despite arising from a single cell ( Fig. 5D and Supplementary Fig. 4 ). 5F ). Parental SUM149 cells that exited mitosis with CDK2 low phenotype were p21 positive by immunofluorescence (Fig. 5G) , as previously observed in non-cancer models [12] . These results suggest that DNA damage and p21 expression may in part determine CDK2 activity state at mitotic exit [22] .
Inhibition of PI3 kinase synergizing with CDK4/6 inhibitors in PIK3CA mutant TNBC
The non-basal, LAR and MSL subtypes of TNBC are substantially enriched with activating mutations in the PI3 kinase catalytic subunit PIK3CA gene [23] , and therefore we investigated the therapeutic potential of PI3 kinase pathway inhibitors in TNBC. A synergistic interaction (Bliss additivity score < -1.0) was observed between the pan class I PI3 kinase inhibitor pictilisib (GDC0941) and palbociclib in PIK3CA mutant TNBC cell lines (Fig. 6A) , as we recently reported in ER+ve cell lines [10] . Combination synergy was not observed in PIK3CA wild-type cell lines nor the RB1 mutant cell line BT549. Synergy was also observed with mTOR inhibitor AZD2014 -palbociclib combinations in PIK3CA mutant and some PIK3CA wild-type TNBC cell lines (Supplementary Fig. 5A ). We further validated the efficacy of the drug combination with theα-selective PI3 kinase inhibitor taselisib (GDC0032), which substantially sensitised the MSL cell line SUM159 to palbociclib in clonogenic assays (Fig.   6B ) and BrdU proliferation assays (Supplementary Fig. 5B ). These data suggested that combinations of PI3 kinase pathway inhibitors and CDK4/6 inhibitors could extend the utility of CDK4/6 inhibitors outside LAR subtype cancers. 5C ).
Finally, we examined whether PI3 kinase inhibition with taselisib affected post-mitotic CDK2 levels, using the PIK3CA mutant MES CAL51 cell line. Taselisib decreased post-mitotic CDK2 activity with a greater proportion of cell that exit mitosis CDK2 low (Fig. 6E) . Pre-mitotic CDK2 levels influenced entry into the cell cycle post-mitosis ( Supplementary Fig. 5D ).
These data suggested that the PI3 kinase inhibition sensitised to CDK4/6 inhibition, in part as PI3 kinase inhibition suppressed post mitotic CDK2 activity, inducing a CDK2 low quiescent state where CDK4/6 activity was required to initiate the cell cycle.
Discussion
We have shown that the luminal androgen receptor (LAR) subgroup of triple negative breast cancers (TNBC) is highly sensitive to CDK4/6 inhibition in vitro and in vivo (Fig. 1 ).
Sensitivity to CDK4/6 inhibition is dictated at the single cell level, with resistance to CDK4/6 inhibitors arising from cancer cells that exit mitosis directly into a CDK2 high proliferative state, from which CDK4/6 is not necessary for cell cycle re-entry ( Fig. 2C and Fig.3A) .
Our results further extend prior work in non-cancer models that demonstrate a biphasic exit of cells into proliferative and quiescent states after mitosis [12, 13] . Cells that exit mitosis with a CDK2 low phenotype enter into a quiescent state, requiring CDK4/6 activity to initiate reentry into the cell cycle (Fig. 6F) , and are hence sensitivity to CDK4/6 inhibition. In contrast, cells that exit mitosis with a CDK2 high phenotype enter into a proliferative state, bypassing the restriction point (Fig. 6G) , with short doubling times. Tumours with a high proportion of (Fig. 4D) . Dysregulated cyclin E1 promotes the CDK2 high phenotype with CDK2-CyclinE complex active immediately post-mitosis resulting in short G1 phase (Fig. 6G ).
SUM149 harbour an inactivating FBXW7 mutation that disrupts the SCF complex and likely contributes to dysregulated cyclin E1 expression (Supplementary table 2) . In other contexts, increased CCNE1 gene copy number probably contributes to dysregulation of cyclin E1 expression post-mitosis [10] . These observations suggest that measurement of cyclin E1 expression either at the RNA or protein level has the potential to be utilised as a predictive biomarker of resistance to CDK4/6 inhibition in breast cancer.
Daughter cells share the same CDK2 activity state, suggesting that post-mitotic CDK2 activity is determined pre-mitosis (Fig. 5A ). However, this is not the result of CDK2 high and CDK2 low cells, as colonies derived from individual cells largely recapitulate the same variability in CDK2 activity as the parental cell line (Fig. 5D ). We provide some data to suggest that DNA damage, and the resulting induction of p21 expression, may also regulate CDK2 activity state post-mitosis (Fig. 5G) . However, more research is required to further assess the potential role of DNA damaging signalling in this context. 
